Similar articles

• Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.

  Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Chertow GM; ADVANCE Study group. Floege J, et al. Nephrol Dial Transplant. 2010 Jun;25(6):1916-23. doi: 10.1093/ndt/gfp762. Epub 2010 Jan 27. Nephrol Dial Transplant. 2010. PMID: 20110249 Clinical Trial.
• The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.

  Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J; ADVANCE Study Group. Raggi P, et al. Nephrol Dial Transplant. 2011 Apr;26(4):1327-39. doi: 10.1093/ndt/gfq725. Epub 2010 Dec 8. Nephrol Dial Transplant. 2011. PMID: 21148030 Clinical Trial.
• Change in coronary artery calcification score due to cinacalcet hydrochloride administration.

  Tsuruta Y, Ohbayashi T, Fujii M, Myochin H, Mizutani R, Narita M, Maeda K. Tsuruta Y, et al. Ther Apher Dial. 2008 Oct;12 Suppl 1:S34-7. doi: 10.1111/j.1744-9987.2008.00629.x. Ther Apher Dial. 2008. PMID: 19032525 Clinical Trial.
• Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.

  Iseki K. Iseki K. Expert Opin Pharmacother. 2008 Mar;9(4):601-10. doi: 10.1517/14656566.9.4.601. Expert Opin Pharmacother. 2008. PMID: 18312161 Review.
• [Cinacalcet therapy and cardiovascular risk in hemodialysis patients].

  Zelaźnicka M, Kocełak P, Olszanecka Glinianowicz M, Chudek J. Zelaźnicka M, et al. Postepy Hig Med Dosw (Online). 2012 Oct 22;66:722-9. doi: 10.5604/17322693.1015034. Postepy Hig Med Dosw (Online). 2012. PMID: 23175326 Review. Polish.